Relay Therapeutics, Inc.(RLAY)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Relay Therapeutics, Inc. (RLAY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RLAY at 19.5/100 on a 32-signal composite quality model, placing it at rank #2,791 of 2,961 stocks — the bottom half of the AI-ranked universe. RLAY scores in the top quartile across institutional flow (94.6). Areas of concern include profitability (1.4) and free cash flow (1.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Relay Therapeutics, Inc. reports quarterly revenue of $350.0K, net income of $-83.7M. Top institutional holders of RLAY by reported 13-F value include SB INVESTMENT ADVISERS (UK) LTD, FMR, Casdin Capital, based on the most recent SEC filings. RLAY trades on the Nasdaq exchange and files with the SEC under CIK 1812364. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RLAY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Relay Therapeutics, Inc. directly from SEC EDGAR.